Stryker

史赛克

(NYSE: SYK)

（纽约证券交易所代码：SYK）

+

加号

announced

宣布

today that it completed its previously announced acquisition of

今天，它完成了之前宣布的收购

Inari Medical

Inari Medical

.

。

The Portage, Michigan-based orthopedic giant announced last month that it

密歇根州波特奇的骨科巨头上个月宣布

struck a deal to acquire Inari worth $4.9 billion

达成了一项价值49亿美元的收购Inari的交易

. Inari develops solutions for venous thromboembolism (VTE) clot removal without the use of thrombolytic drugs.

Inari 开发了无需使用溶栓药物的静脉血栓栓塞症 (VTE) 血栓清除解决方案。

Stryker believes adding Inari brings an established peripheral vascular position to the company in the fast-growing VTE segment.

史赛克认为，加入Inari将为公司在快速增长的VTE领域中带来一个成熟的外周血管地位。

“The acquisition of Inari Medical marks a significant milestone in expanding our interventional endovascular portfolio,” said Kevin Lobo, chair and CEO, Stryker. “We look forward to welcoming the talented Inari team to Stryker and working together to improve outcomes for patients worldwide.”

“收购Inari Medical标志着我们拓展介入血管产品组合的一个重要里程碑，”Stryker董事长兼首席执行官凯文·罗博表示。“我们期待欢迎才华横溢的Inari团队加入Stryker，并共同努力改善全球患者的治疗效果。”

Stryker said Inari’s product portfolio is highly complementary to its Neurovascular business unit. It includes two thrombectomy solutions — FlowTriever for treating pulmonary embolism (PE) and ClotTriever for thrombectomy in the peripheral vessels — plus emerging therapies.

史赛克表示，Inari的产品组合与其神经血管业务部门高度互补。它包括两种血栓切除解决方案——用于治疗肺栓塞（PE）的FlowTriever和用于外周血管血栓切除的ClotTriever——以及新兴疗法。

Inari’s portfolio includes

Inari的产品组合包括

nitinol

镍钛诺

-enabled devices and systems like the FlowTriever for pulmonary embolism (PE), ClotTriever for deep vein thrombosis (DVT), LimFlow system for chronic limb-threatening ischemia (which

启用的设备和系统，如用于肺栓塞（PE）的FlowTriever、用于深静脉血栓（DVT）的ClotTriever、以及用于慢性肢体威胁性缺血的LimFlow系统（这

Inari purchased for up to $415 million in 2023

2023年，Inari以高达4.15亿美元的价格被收购。

), and the new

），以及新的

Artix thrombectomy system for acute limb ischemia

Artix血栓切除系统用于急性肢体缺血

.

。

The terms of the deal see Stryker acquire all outstanding shares of Inari common stock for $80 per share. All conditions of the cash tender offer have been satisfied, Stryker says. Upon the completion fo the deal, Inari became a wholly owned subsidiary of Sryker.

交易条款显示，史赛克将以每股80美元的价格收购所有未偿的Inari普通股。史赛克表示，现金要约收购的所有条件均已满足。交易完成后，Inari成为史赛克的全资子公司。